novartis ag novartis ag defended its stance on drug patents as a court case began in india saying tighter intellectual property laws would spur investment in new medicines india is a source of inexpensive generic medicines but the swiss pharmaceuticals company is challenging an indian law that blocks the patenting of minor improvements in known molecules novartis is also challenging a january decision to reject its patent application in india for cancer drug glivec known in the u s as gleevec that was turned down because it was for a new form of a known substance 
